re: coramsine/spike/egr Hey Spike , which broader market are you talking about , PGL , for instance was valued at a market cap of approx 11.5 m in 2003(dog status in your opinion) , before the end of their phase 1 trials and is now sitting with a market cap of around 200m on results so far and have not even finished phase 2 . Thats almost a 20 bagger . I could live with that .
I think you probably can foresee how Solbecs cancer trial results will look in comparison .
EGR , coramsine is going to be too late for what by 2005 ?
I get the impression that Solbec is being held up to higher standards than the rest of the industry . I know that PGL went to $14 , but that was before the techwreck burst that bubble . They dropped to the 40-50c range during the four years of phase 1 trials . The technology proved itself in the clinicals and has come back to the $5-$6 range . Same board .
Cheers
SBP
solbec pharmaceuticals limited
